Plants, Yeast and Cancer Cells
BSc Zoology + Vocational Biotechnology. Research focus: Plant tissue culture (Rose and Emerald Frond)
MSc Molecular Biology. Research Focus: Randomly Amplified Polymorphic DNA in Tobacco.
PhD Biochemistry. Research Focus: Senescence bypass by Telomere Recombination in Yeast cells.
Post-Doctoral Fellowship Cancer Therapeutics. Understanding the impact of telomerase inhibition on cancer stem cells.
Scientist Cancer Therapeutics. Understanding the molecular pathways behind the effect of telomerase inhibition on cancer stem cells. Discovering new therapeutic interventions targeting cancer stem cells.
Scientific Publications/ Invited Talks
Joseph I*, Tressler R, Bassett E et al, The Telomerase Inhibitor Imetelstat Depletes
Cancer Stem Cells in Breast and Pancreatic Cancer Cell Lines. Cancer Research,
Nov-15th, 2010. *Corresponding Author.
Joseph I, Jia D, Lustig AJ. Ndj1p-dependent epigenetic resetting of telomere size in yeast
meiosis. Current Biology 2005;15(3):231-237.
Joseph I, Lustig AJ. Telomeres and meiosis in health and disease: Telomeres in meiotic
recombination: The Yeast Side Story. Cell and Molecular Life Sciences
2007;64(2):125-30.
Joseph I. Cancer stem cells, Casein Kinase -2 and a Telomerase inhibitor drug. Sri Ramachandra Medical University, India. June 8th, 2012.
Joseph I, Bhattacharyya MK, Lustig AJ. An mre11 Mutation that Promotes Telomere
Recombination and an Efficient Bypass of Senescence. Genetics. July 2010 185:761-770.
Nitta R, Go N, Avilion A and Joseph I*. Editor: M.A. Hayat. Inhibition of telomerase
with imetelstat causes depletion of cancer stem cells. Book Chapter.
Therapeutic Applications in Disease and Injury-Volume 5: Stem cells and cancer stem
cells, 2011. (Springer Publishing, New York). *Corresponding Author
Joseph I. The telomerase inhibitor imetelstat perturbs key signaling pathways in cancer stem cells. International Conference and Exhibition on Cell Science and Stem Cell Research. Philadelphia Nov 29th to Dec 1st, 2011.
Poster Presentations (Selected)
01.
Nitta R, O’Sullivan C, Wang H, Ramiya A, Boorsma KD, Lin T, Kashani H and Joseph I*.
Proceedings of the 2011 AACR-NCI-EORTC International Conference on Molecular
Targets and Cancer Therapeutics; 2011 Nov 12-16; San Francisco, California.
Philadelphia (PA): AACR; Mol Cancer Ther 2011;10 (11 Suppl): Abstract nr A56. *
Presenter
02.
Joseph I, Matsui W, La-Porta C et al. Imetelstat, a telomerase inhibitor in phase I trials
in solid tumor and hematological malignancies, has broad activity against multiple
types of cancer stem cells. Selected for Poster presentation, AACR 101st Annual Meeting
2010,Washington, DC. April 17-21 2010.
03.
Joseph I, Matsui W, La-Porta C et al. In vivo and in vitro inhibition of multiple types of
cancer stem cells by the novel telomerase inhibitor imetelstat. Selected for Talk and
Poster presentation, AACR Special Conference on The Role of Telomeres and
Telomerase in Cancer Research, Fort Worth, Texas February 27-March 2, 2010
04.
Joseph I, Bassett E, Tressler R et al. GRN163L (Imetelstat sodium) diminishes the self renewal capacity of putative cancer stem cells from human breast and pancreatic cell lines and decreases tumorigenic potential. AACR 100th Annual Meeting, Colorado, Denver. April 18-22, 2009.
05.
Bassett E, Ushach I, Joseph I et al, Telomere shortening in cancer cells following in vitro and in vivo treatment with telomere inhibitor imetelstat sodium (GRN163L). AACR 100th Annual Meeting, Colorado, Denver. April 18-22, 2009.
06.
Joseph I, Bhattacharyya MK, Lustig AJ. Recombination mediated senescence bypass in a novel allele of Mre11. Presented as a poster at the Telomeres and Telomerase Meeting, Cold Spring Harbor Lab. Cold Spring Harbor, New York, May 2-6, 2007